Basilea Pharmaceutica Valuation
Is BSLNz undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BSLNz when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BSLNz (CHF42.6) is trading below our estimate of fair value (CHF145.47)
Significantly Below Fair Value: BSLNz is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BSLNz?
Other financial metrics that can be useful for relative valuation.
| What is BSLNz's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | -100.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BSLNz's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.1x | ||
OXB Oxford Biomedica | 4.5x | 21.0% | UK£439.4m |
BVXP Bioventix | 14x | n/a | UK£190.5m |
GNS Genus | 1.9x | 3.5% | UK£1.3b |
AVCT Avacta Group | 8.1x | 14.3% | UK£182.9m |
BSLNz Basilea Pharmaceutica | 3.5x | 9.2% | CHF 515.1m |
Price-To-Sales vs Peers: BSLNz is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (7.1x).
Price to Earnings Ratio vs Industry
How does BSLNz's PE Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Sales vs Industry: BSLNz is good value based on its Price-To-Sales Ratio (3.5x) compared to the European Biotechs industry average (8.6x).
Price to Sales Ratio vs Fair Ratio
What is BSLNz's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.5x |
| Fair PS Ratio | 1.7x |
Price-To-Sales vs Fair Ratio: BSLNz is expensive based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 42.60 | CHF 74.87 +75.7% | 35.7% | CHF 120.00 | CHF 44.20 | n/a | 6 |
| Nov ’25 | CHF 43.48 | CHF 74.87 +72.2% | 35.7% | CHF 120.00 | CHF 44.20 | n/a | 6 |
| Oct ’25 | CHF 45.45 | CHF 73.20 +61.1% | 32.8% | CHF 110.00 | CHF 44.20 | n/a | 6 |
| Sep ’25 | CHF 46.10 | CHF 72.37 +57.0% | 32.0% | CHF 110.00 | CHF 44.20 | n/a | 6 |
| Aug ’25 | CHF 39.80 | CHF 71.20 +78.9% | 30.5% | CHF 105.00 | CHF 44.20 | n/a | 6 |
| Jul ’25 | CHF 39.30 | CHF 71.20 +81.2% | 30.5% | CHF 105.00 | CHF 44.20 | n/a | 6 |
| Jun ’25 | CHF 43.80 | CHF 70.58 +61.1% | 31.9% | CHF 105.00 | CHF 40.50 | n/a | 6 |
| May ’25 | CHF 39.65 | CHF 70.58 +78.0% | 31.9% | CHF 105.00 | CHF 40.50 | n/a | 6 |
| Apr ’25 | CHF 37.63 | CHF 69.08 +83.6% | 30.6% | CHF 105.00 | CHF 40.50 | n/a | 6 |
| Mar ’25 | CHF 35.10 | CHF 69.08 +96.8% | 30.6% | CHF 105.00 | CHF 40.50 | n/a | 6 |
| Feb ’25 | CHF 33.00 | CHF 64.38 +95.1% | 24.7% | CHF 85.00 | CHF 40.50 | n/a | 4 |
| Jan ’25 | CHF 35.40 | CHF 70.70 +99.7% | 26.5% | CHF 91.00 | CHF 40.50 | n/a | 5 |
| Dec ’24 | CHF 34.70 | CHF 75.68 +118.1% | 19.8% | CHF 91.00 | CHF 57.70 | n/a | 4 |
| Nov ’24 | CHF 35.45 | CHF 73.28 +106.7% | 20.1% | CHF 91.00 | CHF 52.00 | CHF 43.48 | 6 |
| Oct ’24 | CHF 40.90 | CHF 70.44 +72.2% | 21.7% | CHF 91.00 | CHF 52.00 | CHF 45.45 | 7 |
| Sep ’24 | CHF 47.90 | CHF 70.44 +47.1% | 21.7% | CHF 91.00 | CHF 52.00 | CHF 46.10 | 7 |
| Aug ’24 | CHF 43.70 | CHF 70.44 +61.2% | 21.7% | CHF 91.00 | CHF 52.00 | CHF 39.80 | 7 |
| Jul ’24 | CHF 41.85 | CHF 67.18 +60.5% | 21.0% | CHF 91.00 | CHF 52.00 | CHF 39.30 | 6 |
| Jun ’24 | CHF 45.60 | CHF 67.18 +47.3% | 21.0% | CHF 91.00 | CHF 52.00 | CHF 43.80 | 6 |
| May ’24 | CHF 43.30 | CHF 72.07 +66.4% | 20.8% | CHF 91.00 | CHF 52.00 | CHF 39.65 | 6 |
| Apr ’24 | CHF 50.20 | CHF 74.80 +49.0% | 18.4% | CHF 91.00 | CHF 52.00 | CHF 37.63 | 5 |
| Mar ’24 | CHF 52.30 | CHF 68.98 +31.9% | 26.2% | CHF 91.00 | CHF 39.90 | CHF 35.10 | 6 |
| Feb ’24 | CHF 48.85 | CHF 73.82 +51.1% | 34.7% | CHF 120.00 | CHF 39.90 | CHF 33.00 | 6 |
| Jan ’24 | CHF 45.80 | CHF 69.15 +51.0% | 26.2% | CHF 91.00 | CHF 39.90 | CHF 35.40 | 6 |
| Dec ’23 | CHF 49.75 | CHF 68.58 +37.8% | 28.9% | CHF 91.00 | CHF 39.90 | CHF 34.70 | 5 |
| Nov ’23 | CHF 46.80 | CHF 74.48 +59.2% | 34.4% | CHF 120.00 | CHF 39.90 | CHF 35.45 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.